AstraZeneca’s Autoimmune Medicine Reduced Disease Severity

AstraZeneca Plc’s experimental drug for a rare autoimmune disorder helped patients control their disease, the company said, boosting prospects for the potential blockbuster medicine.

The injectable drug gefurulimab for generalized myasthenia gravis showed a statistically significant and clinically meaningful reduction in disease severity while helping patients improve their ability to carry out daily tasks, AstraZeneca said in a statement.